https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-832005-01-01 00:00:002019-02-15 08:50:23Immunotherapy and cancer vaccines in the management of breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Nat Clin Pract Urol 2005 Jan;2(1):44-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Nat Clin Pract Urol 2005 Jan;2(1):44-512005-01-01 00:00:002019-02-15 09:24:18Technology Insight: vaccine therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Methods Mol. Med. 2005;109:127-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Methods Mol. Med. 2005;109:127-362005-01-01 00:00:002019-02-15 08:51:03Dendritic cells in clinical trials for multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Vopr Onkol 2005;51(6):685-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Vopr Onkol 2005;51(6):685-82005-01-01 00:00:002019-02-15 08:53:38[Combined radiotherapy and endovascular x-ray therapy for invasive cancer of the urinary bladder]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / BioDrugs 2005;19(5):289-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / BioDrugs 2005;19(5):289-972005-01-01 00:00:002019-02-15 09:25:42Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-17 / Cancer Immunol. Immunother. 2005 Jul;54(7):663-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-17 / Cancer Immunol. Immunother. 2005 Jul;54(7):663-702004-12-17 00:00:002019-02-15 09:17:04Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / J. Urol. 2004 Dec;172(6 Pt 2):2532-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / J. Urol. 2004 Dec;172(6 Pt 2):2532-82004-12-01 00:00:002019-02-15 09:24:22Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / J. Hepatol. 2004 Dec;41(6):999-1007
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / J. Hepatol. 2004 Dec;41(6):999-10072004-12-01 00:00:002019-02-15 09:11:52Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / Minerva Ginecol 2004 Dec;56(6):515-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / Minerva Ginecol 2004 Dec;56(6):515-272004-12-01 00:00:002004-12-01 00:00:00Current approaches in ovarian cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / Gynecol. Oncol. 2004 Dec;95(3):680-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / Gynecol. Oncol. 2004 Dec;95(3):680-52004-12-01 00:00:002019-02-15 08:35:32Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer
